nach oben

Erschienen in:

15.07.2020 | Letter to the Editor

A case of “double hit” mantle cell lymphoma carrying CCND1 and MYC translocations relapsed/refractory to rituximab bendamustine cytarabine (R-BAC) and ibrutinib

verfasst von: Greta Scapinello, Marcello Riva, Antonio Branca, Marco Pizzi, Laura Bonaldi, Annalisa Martines, Sabrina Manni, Andrea Visentin, Livio Trentin, Gianpietro Semenzato, Carmela Gurrieri, Francesco Piazza

Erschienen in: Annals of Hematology | Ausgabe 11/2020

Einloggen, um Zugang zu erhalten

Excerpt

Dear Editor, …

(1997) A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphoma. The Non-Hodgkin’s Lymphoma Classification Project. Blood 89(11):3909–3918

Sander B, Quintanilla-Martinez L, Ott G, Xerri L, Kuzu I, Chan JK, Swerdlow SH, Campo E (2016) Mantle cell lymphoma--a spectrum from indolent to aggressive disease. Virchows Arch 468(3):245–257. https://doi.org/10.1007/s00428-015-1840-6CrossRefPubMed

Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, Advani R, Ghielmini M, Salles GA, Zelenetz AD, Jaffe ES (2016) The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 127(20):2375–2390. https://doi.org/10.1182/blood-2016-01-643569CrossRefPubMedPubMedCentral

Visco C, Finotto S, Zambello R, Paolini R, Menin A, Zanotti R, Zaja F, Semenzato G, Pizzolo G, D’Amore ES, Rodeghiero F (2013) Combination of rituximab, bendamustine, and cytarabine for patients with mantle-cell non-Hodgkin lymphoma ineligible for intensive regimens or autologous transplantation. J Clin Oncol 31(11):1442–1449. https://doi.org/10.1200/JCO.2012.45.9842CrossRefPubMed

Tisi MC, Paolini R, Piazza F, Ravelli E, Tecchio C, Sartori R, Famengo B, D’Amore ESG, Carli G, Perbellini O, Di Bona E, Ruggeri M, Visco C (2018) Rituximab, bendamustine and cytarabine (R-BAC) in patients with relapsed-refractory aggressive B-cell lymphoma. Am J Hematol 93(12):E386–E389. https://doi.org/10.1002/ajh.25278CrossRefPubMed

Tirier C, Zhang Y, Plendl H, Weber-Matthiesen K, Langer W, Heit W, Schlegelberger B (1996) Simultaneous presence of t(11;14) and a variant Burkitt’s translocation in the terminal phase of a mantle cell lymphoma. Leukemia 10(2):346–350PubMed

Bea S, Ribas M, Hernandez JM, Bosch F, Pinyol M, Hernandez L, Garcia JL, Flores T, Gonzalez M, Lopez-Guillermo A, Piris MA, Cardesa A, Montserrat E, Miro R, Campo E (1999) Increased number of chromosomal imbalances and high-level DNA amplifications in mantle cell lymphoma are associated with blastoid variants. Blood 93(12):4365–4374PubMed

Vaishampayan UN, Mohamed AN, Dugan MC, Bloom RE, Palutke M (2001) Blastic mantle cell lymphoma associated with Burkitt-type translocation and hypodiploidy. Br J Haematol 115(1):66–68. https://doi.org/10.1046/j.1365-2141.2001.03056.xCrossRefPubMed

Hernandez L, Hernandez S, Bea S, Pinyol M, Ferrer A, Bosch F, Nadal A, Fernandez PL, Palacin A, Montserrat E, Campo E (1999) C-myc mRNA expression and genomic alterations in mantle cell lymphomas and other nodal non-Hodgkin’s lymphomas. Leukemia 13(12):2087–2093. https://doi.org/10.1038/sj.leu.2401599CrossRefPubMed

10.

Choe JY, Yun JY, Na HY, Huh J, Shin SJ, Kim HJ, Paik JH, Kim YA, Nam SJ, Jeon YK, Park G, Kim JE (2016) MYC overexpression correlates with MYC amplification or translocation, and is associated with poor prognosis in mantle cell lymphoma. Histopathology 68(3):442–449. https://doi.org/10.1111/his.12760CrossRefPubMed

11.

Yi S, Zou D, Li C, Zhong S, Chen W, Li Z, Xiong W, Liu W, Liu E, Cui R, Ru K, Zhang P, Xu Y, An G, Lv R, Qi J, Wang J, Cheng T, Qiu L (2015) High incidence of MYC and BCL2 abnormalities in mantle cell lymphoma, although only MYC abnormality predicts poor survival. Oncotarget 6(39):42362–42371. https://doi.org/10.18632/oncotarget.5705CrossRefPubMedPubMedCentral

12.

Hu Z, Medeiros LJ, Chen Z, Chen W, Li S, Konoplev SN, Lu X, Pham LV, Young KH, Wang W, Hu S (2017) Mantle cell lymphoma with MYC rearrangement: a report of 17 patients. Am J Surg Pathol 41(2):216–224. https://doi.org/10.1097/PAS.0000000000000758CrossRefPubMed

13.

Wang L, Tang G, Medeiros LJ, Xu J, Huang W, Yin CC, Wang M, Jain P, Lin P, Li S (2020) MYC rearrangement but not extra MYC copies is an independent prognostic factor in patients with mantle cell lymphoma. Haematologica. https://doi.org/10.3324/haematol.2019.243071 haematol.2019.243071

14.

Lee J, Zhang LL, Wu W, Guo H, Li Y, Sukhanova M, Venkataraman G, Huang S, Zhang H, Alikhan M, Lu P, Guo A, Galanina N, Andrade J, Wang ML, Wang YL (2018) Activation of MYC, a bona fide client of HSP90, contributes to intrinsic ibrutinib resistance in mantle cell lymphoma. Blood Adv 2(16):2039–2051. https://doi.org/10.1182/bloodadvances.2018016048CrossRefPubMedPubMedCentral

15.

Sun B, Shah B, Fiskus W, Qi J, Rajapakshe K, Coarfa C, Li L, Devaraj SG, Sharma S, Zhang L, Wang ML, Saenz DT, Krieger S, Bradner JE, Bhalla KN (2015) Synergistic activity of BET protein antagonist-based combinations in mantle cell lymphoma cells sensitive or resistant to ibrutinib. Blood 126(13):1565–1574. https://doi.org/10.1182/blood-2015-04-639542CrossRefPubMedPubMedCentral

Titel: A case of “double hit” mantle cell lymphoma carrying CCND1 and MYC translocations relapsed/refractory to rituximab bendamustine cytarabine (R-BAC) and ibrutinib
verfasst von: Greta Scapinello
Marcello Riva
Antonio Branca
Marco Pizzi
Laura Bonaldi
Annalisa Martines
Sabrina Manni
Andrea Visentin
Livio Trentin
Gianpietro Semenzato
Carmela Gurrieri
Francesco Piazza
Publikationsdatum: 15.07.2020
Verlag: Springer Berlin Heidelberg
Erschienen in: Annals of Hematology / Ausgabe 11/2020
Print ISSN: 0939-5555
Elektronische ISSN: 1432-0584
DOI: https://doi.org/10.1007/s00277-020-04178-0

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

A case of “double hit” mantle cell lymphoma carrying CCND1 and MYC translocations relapsed/refractory to rituximab bendamustine cytarabine (R-BAC) and ibrutinib

Excerpt

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11/2020

Use of carbapenems and glycopeptides increases risk for Clostridioides difficile infections in acute myeloid leukemia patients undergoing intensive induction chemotherapy

Biological properties of bone marrow plasma cells influence their recovery in aspirate specimens: impact on classification of plasma cell disorders and potential bias to evaluation of treatment response

Direct comparison of two extended half-life PEGylated recombinant FVIII products: a randomized, crossover pharmacokinetic study in patients with severe hemophilia A

Hepatic and cardiac iron load as determined by MRI T2* in patients with congenital dyserythropoietic anemia type I

Clozapine-induced agranulocytosis

Myelomatous pleural effusion with plasmablastic morphology and high genetic complexity as isolated extramedullary relapse

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin